Play all audios:
Access through your institution Buy or subscribe To cover this gap, Dunlop et al. investigated treatment-naive individuals who remitted after 12 weeks of cognitive behavioral therapy (CBT)
or antidepressant medication (duloxetine or escitalopram). They compared the differences between the functional magnetic resonance imaging resting-state scans at baseline and the scans
repeated after 12 weeks of receiving the randomized treatment. Independently of the remission after CBT or antidepressant medication, both groups displayed a reduction in the functional
connectivity between the subcallosal cingulate cortex and a portion of the motor cortex. “Although we did not have a clinical correlate of motor change, there is an intuitive sense to this
result, in that when people are no longer depressed, they frequently report it to be easier to initiate motor actions, such as getting out of bed or moving quicker from one place to another.
This result raises the possibility that the subcallosal cingulate cortex, a key hub for processing negative affect, may have increased inhibitory input to the motor cortex when people are
depressed and that is ameliorated when people are no longer depressed,” Boadie Dunlop, the first author of the paper, explains. Next, only the CBT remitters exhibited increased connectivity
within the executive control network and between the latter and the dorsal attention network. “This is a key finding because it is precisely through enhancing cognitive control and altering
attention that CBT has been hypothesized to work,” Dunlop adds. In contrast to CBT, medications mostly reduced connectivity within and between networks. These results may ultimately help to
identify individuals who do not need an ongoing exposure to medication, but who would instead benefit from CBT. Finally, the individuals who did not improve with either treatment failed to
show many of the changes that occurred in the remitters. “This finding might enable early identification of patients who should be rapidly moved to non-first-line treatments, such as
ketamine or transcranial magnetic stimulation, or perhaps an alternative evidence-based psychotherapy. Also, our study opens new avenues for distinguishing between state (present only when
depressed) and trait (always present) features of depression,” Dunlop concludes. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your
institution Subscribe to this journal Receive 12 digital issues and online access to articles $79.00 per year only $6.58 per issue Learn more Buy this article * Purchase on SpringerLink *
Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional
subscriptions * Read our FAQs * Contact customer support AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Nature Mental Health https://www.nature.com/natmentalhealth/ Natalia Gass Authors *
Natalia Gass View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Natalia Gass. RIGHTS AND PERMISSIONS Reprints and
permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Gass, N. Circuit-based biomarkers for guiding depression treatment. _Nat. Mental Health_ 1, 162 (2023).
https://doi.org/10.1038/s44220-023-00037-9 Download citation * Published: 22 March 2023 * Issue Date: March 2023 * DOI: https://doi.org/10.1038/s44220-023-00037-9 SHARE THIS ARTICLE Anyone
you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the
Springer Nature SharedIt content-sharing initiative